Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.
BJOG
; 122(1): 107-18, 2015 Jan.
Article
em En
| MEDLINE
| ID: mdl-25208608
ABSTRACT
OBJECTIVE:
Evaluation of the long-term HPV-16/18 AS04-adjuvanted vaccine immunogenicity persistence in women.DESIGN:
Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase-III study (NCT00196937).SETTING:
Six centres in Germany and Poland. POPULATION 488 healthy women (aged 15-55 years, age-stratified into groups 15-25, 26-45, and 46-55 years) who received three vaccine doses in the primary study.METHODS:
Immune responses were evaluated in serum and cervicovaginal secretion (CVS) samples 6 years after dose 1. Anti-HPV-16/18 geometric mean titres (GMTs) were measured by enzyme-linked immunosorbent assay (ELISA), and were used to fit the modified power-law and piecewise models, predicting long-term immunogenicity. Serious adverse events (SAEs) were recorded. MAIN OUTCOMEMEASURES:
Anti-HPV-16/18 seropositivity rates and GMTs 6 years after dose 1.RESULTS:
At 6 years after dose 1, all women were seropositive for anti-HPV-16 and ≥97% were seropositive for anti-HPV-18 antibodies. GMTs ranged from 277.7 to 1344.6 EU/ml, and from 97.6 to 438.2 EU/ml, for anti-HPV-16 and anti-HPV-18, respectively. In all age groups, GMTs were higher (anti-HPV-16, 9.3-45.1-fold; anti-HPV-18, 4.3-19.4-fold) than levels associated with natural infection (29.8 EU/ml). A strong correlation between serum and CVS anti-HPV-16/18 levels was observed, with correlation coefficients of 0.81-0.96 (anti-HPV-16) and 0.69-0.84 (anti-HPV-18). Exploratory modelling based on the 6-year data predicted vaccine-induced anti-HPV-16/18 levels above natural infection levels for at least 20 years, except for anti-HPV-18 in the older age group (piecewise model). One vaccine-related and two fatal SAEs were reported.CONCLUSIONS:
At 6 years after vaccination, immune responses induced by the HPV-16/18 AS04-adjuvanted vaccine were sustained in all age groups.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias do Colo do Útero
/
Infecções por Papillomavirus
/
Papillomavirus Humano 16
/
Papillomavirus Humano 18
/
Vacinas contra Papillomavirus
/
Anticorpos Antivirais
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
BJOG
Assunto da revista:
GINECOLOGIA
/
OBSTETRICIA
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Alemanha